Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer

The purpose of this study is to determine if KM1 is well tolerated with anti-tumor activity in patients diagnosed with recurrent or refractory ovarian cancer, and explore the Recommend Phase 2 Dose (RP2D) of KM1 in the treatment of patients with recurrent or refractory ovarian cancer.

Trial Details

NCT ID

NCT05684731

Phase

PHASE1

Sponsor

Tongji Hospital

Status

RECRUITING

Cancer Type

Ovarian Cancer

Interventions

KM1
Chemotherapy

Locations (sample)

Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

Histologically or cytopathology confirmed epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, except mucinous cancer.
Relapsed/refractory subjects who failed to receive systemic treatment (at least one standard platinum containing regimen); Note: If the disease rel…
Performance status ECOG of 0 or 1.
Life expectancy of at least 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →